Back to results
US 6,416,958 B2Granted
Selective apoptosis of neoplastic cells by an HLA-DR specific monoclonal antibody
AssigneeDendreon Corporation
InventorsDamir Vidovic, Reiner Laus
Life of this patent
Estimating the term…
Abstract
Anti-human major histocompatibility complex (MHC) class II, HLA-DR-specific monoclonal antibodies which can induce apoptosis of HLA-DR positive cells are disclosed. The antibodies are used to specifically eliminate HLA-DR antigen positive tumor cells by cross-linking of HLA-DR. Also disclosed are methods for treating cancer using such antibodies, and compositions containing them.
Claims5
A method of triggering apoptosis, comprising
- administering to a subject, a therapeutically effective amount of an anti-HLA-DR antibody effective to stimulate apoptosis in HLA-DR-expressing tumor cells.
Dependencies are inferred from the claim text.